pad 3

Streptonigrin is a natural product produced by Streptomyces flocculus, has both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor (IC50s: 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD

PAD4-IN-3（compound 4B）是PAD4抑制剂，表现出体内外的抗肿瘤活性。该化合物通过共价连接RGD序列肽修饰的壳聚糖（K-CRGDV），形成增强的氧化应激反应性纳米剂。K-CRGDV-PAD4-IN-3能够主动靶向肿瘤，抑制PAD4活性，阻断中性粒细胞胞外陷阱（NET）的形成，并通过改善肿瘤免疫微环境来响应肿瘤微环境。

3-O-Methyldopa-d3 是 3-O-Methyldopa 的氘代化合物。3-O-Methyldopa 的 CAS 号为 300-48-1。

Methyldopa-d3 是 Methyldopa 的氘代化合物。Methyldopa 的 CAS 号为 6014-30-8。

MCPA-d3 (phenyl-d3) 是 MCPA 的氘代化合物。MCPA 的 CAS 号为 94-74-6。MCPA（Krezone） 是一种高效的苯氧基除草剂。使用 MCPA 会对附近的水资源和土壤资源产生影响。

Cl-amidine hydrochloride 是一种口服有效的PAD抑制剂，可阻断组蛋白3去亚胺化和中性粒细胞胞外陷阱的形成，并提高败血症小鼠的存活率。它可诱导癌细胞凋亡，还可诱导 miR-16 引起细胞周期阻滞。

BB-Cl-Amidine hydrochloride 是一种肽基精氨酸脱胺酶(PAD)的抑制剂。

Resolvin E2 (RvE2) is a member of the specialized pro-resolving mediator (SPM) family of bioactive lipids.1It is produced from eicosapentaenoic acidviaan 18-HEPE intermediate, which is formed by aspirin-acetylated COX-2-mediated oxidation of EPA, by 5-lipoxygenase (5-LO) in human polymorphonuclear (PMN) neutrophils.2,3RvE2 (20 ng/animal) inhibits increases in inflammatory exudate neutrophil infiltration in a mouse model of peritonitis induced by zymosan A .3Hepatic RvE2 levels are increased in mice fed normal chow, as well as in a mouse model of high-fat diet-induced non-alcoholic fatty liver disease (NAFLD), by dietary supplementation with EPA.4Plasma levels of RvE2 are increased by dietary supplementation with fish oil containing ω-3 polyunsaturated fatty acids (PUFAs) in patients with peripheral artery disease or chronic kidney disease.1,5,6 1.Chiang, N., and Serhan, C.N.Specialized pro-resolving mediator network: An update on production and actionsEssays Biochem.64(3)443-462(2020) 2.Tjonahen, E., Oh, S.F., Siegelman, J., et al.Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesisChemistry & Biology131193-1202(2006) 3.Sungwhan, F.O., Pillai, P.S., Recchiuti, A., et al.Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammationJ. Clin. Invest.121(2)569-581(2011) 4.Echeverría, F., Valenzuela, R., Espinosa, A., et al.Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: Involvement of resolvins RvE1/2 and RvD1/2J. Nutr. Biochem.6335-43(2019) 5.Ramirez, J.L., Gasper, W.J., Khetani, S.A., et al.Fish oil increases specialized pro-resolving lipid mediators in PAD (the OMEGA-PAD II trial)J. Surg. Res.238164-174(2019) 6.Barden, A.E., Shinde, S., Burke, V., et al.The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney diseaseProstaglandins Other Lipid Mediat.1361-8(2018)